FDA Tacks on Two More Chinese Drugmakers to Import Ban List

The FDA has banned imports from two additional Chinese drugmakers, ordering that they be detained without examination for failing to meet GMP standards.

Ten drugs from Attix Pharmaceuticals’ API production facility in Shamen, Fujian, were flagged, as were 10 drugs produced at Xiamen Origin Biotech’s supplement plant in the same region.